Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Morphic Holding Inc Market Cap
From what 1 stock analysts predict, the share price for Morphic Holding Inc (MORF) might increase by 22.08% in the next year. This is based on a 12-month average estimation for MORF. Price targets go from $46.00 to $46.00. The majority of stock analysts believe MORF is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Morphic Holding Inc has a total of 1 Wall St Analyst ratings. There are 1 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Morphic Holding Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| julian harrison BTIG | Hold | None | maintained | Jan 1, 2024 |
| samantha semenkow Citi | Buy | $46.0 | initiatedcoverage | Dec 8, 2023 |
| evan seigerman BMO Capital | Buy | $52.0 | rated | Nov 6, 2023 |
| ritu baral TD Cowen | Buy | None | maintained | Nov 5, 2023 |
| edward nash Canaccord Genuity | Buy | $68.0 | maintained | Nov 5, 2023 |
| gregory renza RBC Capital | Buy | $76.0 | maintained | Nov 3, 2023 |
| alex thompson cfa Stifel Nicolaus | Hold | $27.0 | maintained | Oct 13, 2023 |
| derek archila Wells Fargo | Buy | $80.0 | maintained | Sep 22, 2023 |
| gaurav goparaju Berenberg Bank | Buy | $80.0 | reiterated | Aug 3, 2023 |
| mike kratky SVB Securities | Buy | $60.0 | maintained | Apr 25, 2023 |
| thomas smith SVB Securities | Buy | $45.0 | maintained | Feb 8, 2023 |
| gary nachman BMO Capital | Buy | $83.0 | maintained | Nov 3, 2022 |
| matthew luchini BMO Capital | Buy | $102.0 | reiterated | Nov 5, 2021 |
| do kim Piper Sandler | Buy | $102.0 | maintained | May 31, 2021 |
| michael yee Jefferies | Buy | $115.0 | maintained | Mar 2, 2021 |
| yanan zhu Wells Fargo | Buy | $103.0 | maintained | Mar 1, 2021 |
| jim birchenough Wells Fargo | Buy | $31.0 | initiatedcoverage | Jul 22, 2019 |
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
When did it IPO
2019
Staff Count
115
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Praveen P. Tipirneni M.D.
Market Cap
$1.87B
In 2023, MORF generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MORF's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
NEO-USD
$14.36
PTCT-USD
$25.91
$33.02
MRCY-USD
$29.13
EXPI-USD
$11.06
PTON-USD
$4.54
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
